Q1 2023 Report

11-fold increase in sales revenue compared to the same period last year 42.6% increase in the number of CTG tests performed on Pregnabit Pro devices compared to the same period last year Signed a distribution agreement and obtained a certificate issued by the Israeli Ministry of Health, allowing the platform to be sold on the Israeli market Consistently pursuing FDA certification – conducted tests for electromagnetic compliance, as well as tests for compliance with other points of the relevant standards, some of which have already been successfully completed This is a brief summary of what we did in the first quarter of 2023.